Owkin and Sanofi SA (NASDAQ:SNY) on Friday announced they have expanded their partnership through a new multi-year collaboration focused on developing next-generation AI-powered biopharma agents to support drug discovery and development.
The agreement also includes a five-year license for Owkin's AI Scientist platform, K Pro, marking the latest phase in a relationship that began in 2021.
Partnership Builds On Existing AI Research Efforts
The companies first teamed up through a 90 million euro strategic partnership centered on oncology target identification and patient subgroup analysis.
The collaboration was later broadened to support drug positioning efforts within Sanofi's immunology pipeline.
